Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-carnosine + methylphenidate is a combination therapy involving the dietary supplement l-carnosine and the pharmaceutical stimulant methylphenidate. This combination has been studied as an adjunctive treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methylphenidate acts primarily as a central nervous system stimulant by inhibiting the reuptake of dopamine and norepinephrine, increasing their synaptic concentrations. L-carnosine is a naturally occurring dipeptide with antioxidant properties, proposed to have neuroprotective effects and possible modulatory action on neurotransmitter systems such as GABA and NMDA receptors. Clinical studies suggest that adding l-carnosine to methylphenidate may improve some ADHD symptoms, particularly inattention, according to parent ratings; however, evidence remains limited and further research is needed[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-carnosine + methylphenidate.